insitro

Meet Jana Mitchell, PhD, a principal scientist focusing on ALS research at insitro! She recently showcased how her team is using ML in #ALS, focusing on phenotypic discovery, at ISSCR 2024. They are building innovative models, constructed using iPSC-derived motor neurons, in order to provide novel insights into ALS pathology and potential therapeutic targets. Jana’s takeaways from ISSCR: 🧫 A reminder of why I got into the life sciences 💭 Deep dive sessions were her favorite parts 👀 I can see how the whole field is advancing Jana and her colleagues are harnessing the power of #ML to identify subtle disease patterns that may elude even the most trained human eye. By merging insitro's core technologies — automated iPSC-based cell differentiation and machine learning-driven target discovery — we can unlock new methods for examining human cell types, advancing drug discovery. For more on Jana, see her insitrocyte profile below.

How can #machinelearning help us find better medicines and reinvent #drugdiscovery? Join insitro CEO and founder Daphne Koller on Monday in Boston at Fierce Biotech’s #FierceBiotechSummit 2024 for the kick-off keynote. She will take you inside insitro, diving deep into what the #AI wave means for discovery including: 🧬 Why a “quiet” revolution in #biology is just as significant as the AI revolution 📊 How high-quality data and AI are uncovering novel drug targets  🚀 What we’re doing to find new therapies for the patients who can benefit most Catch the future of therapeutics discovery and development. Learn more and register: https://lnkd.in/gZiJ8nHE

insitro VP, Metabolic Disease David Lloyd is set to shine ✨ at the 8th Annual MASH Drug Development Summit in Boston! He’ll be sharing his expert insights 👨🔬 on how #machinelearning is revolutionizing genetic target discovery and novel therapies for #MASH.

Check it out! Last week Christoph Klein, our director of software engineering, presented to a terrific 200 crowd for Biocom California’s Converge Meet-Up event co-hosted by Bits in Bio and Nucleate. He joined speakers from InstaDeep, ThinkingNode Life Science, Inc., NVIDIA, EvolutionaryScale and Sphinx Bio. Thank you to all the organizers for putting on such a lovely event to network, compare notes, and find more opportunities to cross-pollinate. Christoph presented how insitro built and invested in “POSH” (Pooled Optical Screening in Human cells). He talked about all the ways our software teams worked closely with our wet lab scientists to build and scale this unique capability to perform genetic screening up to genome-wide scale.  ➡️ What is POSH? 🎯 It enables unbiased target discovery and is powered by #machinelearning 🧬 It combines high throughput gene editing with multimodal image-based phenotyping 🔬It investigates perturbations of cellular systems – at scale – to develop better therapeutic targets 🧠 It works across different disease areas and imaging modalities, making it a versatile discovery engine POSH helps us decode biology and find better starting points for new medicines. 🌟 If you want to work on POSH or one of the other bleeding edge platform tools our team is inventing and/or building, check out our careers page. https://lnkd.in/eTueFdYN

What is Possible? Reinventing drug discovery. That is the topic Daphne Koller explores in depth with Reid Hoffman and Aria Finger on their signature Possible podcast. It starts with the ability to measure #biology at high fidelity and scale, across multiple modalities – a perfect opportunity for #machinelearning. That enables us to do more by “taking the data you get and creating from it the data that you don’t have,” as Daphne describes it - opening the door to new insights on disease that underpin new therapeutic interventions. Tune in to hear: 🔬 how we uncover new therapeutic hypotheses  🤝 the distinction between personalized and personal medicine  📈 why exponential curves are deceptive 💬 what her postdoc advisor Stuart Russell asked that made Daphne’s jaw drop  📖  a surprising book pick that helps Daphne stay optimistic Spoiler alert - it’s not in the life sciences, but about our shared long term future. “Not the End of the World: How We Can Be the First Generation to Build a Sustainable Planet.” 📕 Don’t miss this exciting conversation from the industry’s best. Listen below. ⏬

Drum roll… insitro joins Fast Company’s 2024 100 Best Workplaces for Innovators list! Proud to be #21 and to be home to leading minds in #drugdiscovery and #machinelearning to bring better medicines faster to the patients who can benefit most. We believe the solution to the toughest challenges in medicine lies at the intersection of machine learning and tremendous advances in biology. That’s why we foster bilingualism so life scientists and computational scientists as well as engineers and researchers can learn from each other and work side by side. No surprise: two of our core values are to “be bold” and “create together.” #FCBESTWORKPLACES recognizes this unique culture, where creativity thrives and collaboration is natural. Kudos to all the other innovators bringing people together to push the boundaries in their fields. Check out the list: https://lnkd.in/dJJEm8K4

This summer, insitro hosted an exceptional group of students taking a pause from their BS, MS or Ph.D. studies. They hailed from near –  University of California, Berkeley, Caltech, University of California, San Francisco, Stanford University – and far – University of Toronto, Cornell University, New York University, Massachusetts Institute of Technology, Harvard University and Carnegie Mellon University – to name a few. These “insitrocytes for a summer” immersed themselves in #ML-driven drug discovery research and helped advance our mission to find better medicines faster for the patients who can benefit most. Their projects explored both scientific and engineering problems: from advanced ML to uncover insights into gene behavior to designing large-scale genomic studies to developing models for single-cell data analysis. The summer was also about curiosity, exploration, and team-building. They had lively conversations, exchanged ideas and enriched the community at insitro. A special shout-out to our intern mentors for their guidance, as we nurture the next generation of innovators. Thank you to our interns: we can’t wait to see what you do next to help shape the future of medicine. Summer may be over, but several have extended their projects, so more to come. Thanks to all for an inspiring season of innovation. Here's to biotech's future!

Today, insitro founder and CEO Daphne Koller was named to TIME’s 2024 #TIME100AI list! Daphne joins 99 other influential voices in #AI who are shaping critical conversations about its impact on our world. This recognition reflects her vision and leadership, which are at the heart of insitro’s mission to bring better medicines faster to the patients who can benefit most. As #AI continues to transform so many industries, we're honored to work towards the aspiration of making a healthier world. Congratulations to Daphne and all the incredible recipients on this well-deserved recognition! 👏🏼 Read more: https://lnkd.in/eZ8D7Szp

Terrific listening to our CEO Daphne Koller and Jeffrey Reid of the Regeneron Genetics Center compare notes on #AI, genetics, #DEI, and talent pathways. They reinforced the urgent task of improving medicines for patients on Regeneron's new podcast, "The Nucleus." It was great to kick off the series by dissecting the underappreciated revolution in human biology “to quantitatively measure biology at high fidelity and at a high scale” and what it means for drug discovery, plus much more. Here are a few of our favorite insights from Daphne’s conversation with Jeff: 1. Why ML is essential for data-driven biology: With the explosion of tools to measure biological systems at various scales, "there's just no way for the human mind to assimilate and extract the information." But Daphne noted that “while you can interrogate biology at the level of cells, ultimately what you care about is curing humans, not cells," which is why insitro incorporates high-content human clinical data into our discovery strategy. 2. Why genetic diversity opens new windows: The more diverse the data from human genetics, the more we can explore new findings for drug discovery. Daphne shared that “variants that are only relevant in a certain subset of the population are often new windows into disease.” This is why it’s so critical “to create larger, more diverse population cohorts and make sure that they are accessible to the broader research population.” 3. Why we are using a pipeline through platform approach: insitro is building a pipeline through platform and is taking inspiration from life sciences pioneers like Regeneron. Our ML analysis models are generating and prioritizing therapeutic hypotheses, which provide the foundation for a discovery engine that will build value again and again. Daphne talked about her excitement for building a platform “that allows us to generate new therapeutic hypotheses and turn them into medicines.” A big thank you to Jeff and Regeneron for inviting us to be part of the launch of The Nucleus. We're energized by discussions like these with fellow innovators who push the boundaries of science and technology to develop transformative new treatments for patients – and look forward to tuning in to future episodes. For a deeper dive, listen to the full episode of The Nucleus here: https://lnkd.in/etun97D7

Excited to see our first intern cohort diving right in! 👏